The interaction of diltiazem with lovastatin and pravastatin

Clinical Pharmacology and Therapeutics

Volumn 64, Issue 4, 1998, Pages 369-377

  Azie, Nkechi E ^a   Brater, D Craig ^a   Becker, Paula A ^a   Jones, David R ^a   Hall, Stephen D ^a,b  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WISHARD MEMORIAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; CALCIUM ANTAGONIST; DILTIAZEM; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; PRAVASTATIN;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CROSSOVER PROCEDURE; DOSE TIME EFFECT RELATION; DRUG BLOOD LEVEL; DRUG METABOLISM; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; HYPERTENSION; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RHABDOMYOLYSIS; RISK BENEFIT ANALYSIS;

ADMINISTRATION, ORAL; ADULT; ANTICHOLESTEREMIC AGENTS; AREA UNDER CURVE; CARDIOVASCULAR AGENTS; CROSS-OVER STUDIES; CYTOCHROME P-450 ENZYME SYSTEM; DILTIAZEM; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LOVASTATIN; MALE; MIXED FUNCTION OXYGENASES; PRAVASTATIN; REFERENCE VALUES;

EID: 0031718706     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-9236(98)90067-4     Document Type: Article

References (49)

1. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, Macfarlane PW, et al. The West of Scotland Coronary Prevention Study Group: prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995;333:1301-7.
2. The Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-9.
3. Blum CB. Comparison of four inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A reductase. Am J Cardiol 1994;73:3D-11D.
4. Hoeg JM, Brewer HB Jr. 3-Hydroxy-3-methylglutaryl-coenzyme A reductase in the treatment of hypercholesterolemia. JAMA 1987;258:3532-6.
5. DuJovne CA, Chremos AN, Pool JL, Schnaper H, Bradford RH, Shear CL. Expanded clinical evaluation of lovastatin (EXCEL) study results; I: efficacy in modifying plasma lipoproteins and adverse event profile in 8245 patients with moderate hypercholesterolemia. Arch Intern Med 1991;151:43-9.
6. Pan HY, DeVault AR, Wang-Iverson D, Ivashkiv E, Swanson BN, Sugerman AA. Comparative pharmacokinetics and pharmacodynamics of pravastatin and lovastatin. J Clin Pharmacol 1990;30:1128-35.
7. Pentikainen PJ, Saraheimo M, Schwartz JI, Amin RD, Schwartz MS, Brunner-Ferber F, et al. Comparative pharmacokinetics of lovastatin, simvastatin and pravastatin in humans. J Clin Pharmacol 1992;2:136-40.
8. Pan HY, Triscari J, DeVault AR, Smith SA, Wang-Iverson D, Swanson BN, et al. Pharmacokinetic interaction between propranolol and HMG-CoA reductase inhibitor pravastatin and lovastatin. Br J Clin Pharmacol 1991;31:665-70.
9. Pan HY, DeVault AR, Brescia D, Willard DA, McGovern ME, Ivashkiv E. Effect of food on pravastatin pharmacokinetics and pharmacodynamics. Int J Clin Pharmacol Ther Toxicol 1993;31:291-4.
10. Everett D, Chando TJ, Didonato GC, Singhvi SM, Pan HY, Weinstein SH. Biotransformation of pravastatin sodium in humans. Drug Metab Dispos 1991;19:740-8.
11. Jungnickel PW, Cantral KA, Maloley PA. Pravastatin: a new drug for the treatment of hypercholesterolemia. Clin Pharm 1992;11:677-89.
12. Funke PT, Ivashkiv E, Arnold ME, Cohen AI. Determination of pravastatin sodium and its major metabolites in human serum/plasma by capillary gas chromatography/negative ion chemical ionization mass spectrometry. Biomed Environ Mass Spectrom 1989;18:904-9.
13. Robertson RM, Robertson D. Drugs used for the treatment of myocardial ischemia. In: JG Hardman, Limbird LE, editors. Goodman and Gilman's the pharmacological basis of therapeutics. New York: McGraw-Hill; 1996. p. 759-79.
14. Renton KW. Inhibition of hepatic microsomal drug metabolism by the calcium channel blocker diltiazem and verapamil. Biochem Pharmacol 1985;34:2549-53.
15. Varhe A, Olkkola KT, Neuvonen PJ. Diltiazem enhances the effect of triazolam by inhibiting its metabolism. Clin Pharmacol Ther 1996;59:369-75.
16. Carrum G, Egan JM, Abernethy DR. Diltiazem treatment impairs hepatic drug oxidation studies of antipyrine. Clin Pharmacol Ther 1986;40:140-3.
17. Schlanz KD, Myre SA, Bottrff MB. Pharmacokinetic interactions with calcium channel antagonists (part II). Clin Pharmacokinet 1991;21:448-60.
18. Andrade SE, Walker AM, Gottlieb LK, Hollenberg NK, Testa MA, Saperia GM, et al. Discontinuation of antihyperlipidemic drugs-do rates reported in clinical trials reflects rates in primary care settings? N Engl J Med 1995;332:1125-31.
19. Norman DJ, Illingworth DR, Munson J, Hosenpud J. Myolysis and acute renal failure in heart-transplant recipient receiving lovastatin. N Engl J Med 1988;318:46-7.
20. Neuvonen PJ, Jalava KM. Itraconazole drastically increases plasma concentrations of lovastatin and lovastatin acid. Clin Pharmacol Ther 1996;60:54-61.
21. Hsu I, Spinler SA, Johnson NE. Comparative evaluation of the safety and efficacy of HMG-CoA reductase inhibitor monotherapy in the treatment of primary hypercholesterolemia. Ann Pharmacother 1995;29:743-59.
22. Tolbert JA. Efficacy and long term adverse effect pattern of lovastatin. Am J Cardiol 1988;62:28J-34J.
23. Lees RS, Lees AM. Rhabdomyolysis from the co-administration of lovastatin and the antifungal agent itraconazole. N Engl J Med 1995;333:664-5.
24. Spach DH, Bauwens JE, Clark CD, Burke WG. Rhabdomyolysis associated with lovastatin and erythromycin use. West J Med 1991;154:213-5.
25. Yeung PK, Montague TJ, Tsui B, McGregor C. High-performance liquid chromatography assay of diltiazem and 6 metabolites in plasma: application to a pharmacokinetic study in healthy volunteers. J Pharm Sci 1989;78:595-7.
26. Morris MJ, Gilbert JD, Hsieh JYK, Matuszewski BK, Ramjit HG, Bayne WF. Determination of the HMG-CoA reductase inhibitors simvastatin, lovastatin and pravastatin in plasma by gas chromatography/chemical ionization mass spectrometry. Biol Mass Spectrom 1993;22:1-8.
27. Chiou WL. Critical evaluation of the potential error in pharmacokinetic studies of using the linear trapezoidal rule for the calculation of the area under the plasma concentration-time curve. J Pharmacokinet Biopharm 1978;6:539-46.
28. Jacqz E, Hall SD, Branch RA, Wilkinson GR. Polymorphic metabolism of mephenytoin in man: Pharmacokinetic interaction with a coregulated substrate, mephobarbital. Clin Pharmacol Ther 1986;39:646-53.
29. Höglund P, Nilsson LG. Pharmacokinetics of diltiazem and its metabolites after repeated single dosing in healthy volunteers. Ther Drag Monit 1989;11:551-7.
30. Horsmans Y, Desager JP, Van Den Berg V, Abrassart M, Harvengt C. Effects of simvastatin and pravastatin on 6β-hydroxycortisol excretion, a potential marker of cytochrome P450 3A. Pharmacol Res 1993:28:243-8.
31. Transon C, Leeman T, Dayer P. In vitro comparative inhibition profiles of major human drug metabolising cytochrome p450 isoenzymes (CYP2C9, CYP2D6 and CYP3A4) by HMG-CoA reductase inhibitors. Eur J Clin Pharmacol 1996;50:209-15.
32. Kitazawa E, Tamura N, Iwabuchi H, Uchiyama M, Muramatsu S, Takahagi H, et al. Biotransformation of pravastatin sodium. Biochem Biophys Res Commun 1993;192:597-602.
33. Halpin RA, Ulm EH, Till AE, Kari PH, Vyas KP, Hunninghake DB, et al. Biotransformation of lovastatin vs. species differences in vivo metabolite profiles of mouse, rat, dog and human. Drug Metab Dispos 1993;21:1003-11.
34. Wang RW, Kari PH, Lu AY, Thomas PE, Guengrich FP, Vyas KP. Biotransformation of lovastatin; IV: identification of cytochrome P450 3 A proteins as the major enzyme responsible for the oxidative metabolism of lovastatin in rat and human liver microsomes. Arch Biochem Biophys 1990;290:355-61.
35. Vyas KP, Kari PH, Pitzenberger SM, Haipin RA, Ramjit HG, Arison B, et al. Biotransformation of lovastatin: I: structure elucidation of in vitro and in vivo metabolites in the rat and mouse. Drug Metab Dispos 1990;18:203-11.
36. Vyas KP, Kari PH, Wang RW, Lu AY. Biotransformation of lovastatin; III: effect of cimetidine and famotidine on in vitro metabolism of lovastatin by rat and human liver microsomes. Biochem Pharmacol 1990;39:67-73.
37. Gascon MP, Dayer P. In vitro forecasting of drugs which may interfere with the biotransformation of midazolam. Eur J Clin Pharmacol 1991;41:573-8.
38. Brockmöller J, Neumayer HH, Wagner K, Weber W, Heinemeyer G, Kewitz H, et al. Pharmacokinetic interaction between cyclosporin and diltiazem. Eur J Clin Pharmacol 1990;38:237-42.
39. Ahonen J, Dikkola KT, Salmenpera M, Hynynen M, Neuvonen PJ. Effect of diltiazem on midazolam and alfentanil disposition in patients undergoing coronary artery bypass grafting. Anaesthesiology 1996;85:1246-52.
40. Backman J, Olkkola KT, Aranko K, Himberg JJ, Neuvonen PJ. Dose of midazolam should be reduced during diltiazem and verapamil treatments. Br J Clin Pharmacol 1994;37:221-5.
41. Freeman DJ, Martell R, Carruthers SG, Heinrichs D, Keown PA, Stiller CR. Cyclosporin-erythromycin interaction in normal subjects. Br J Clin Pharmacol 1987;23:776-8.
42. Honig PK, Wortham DC, Zamani K, Conner DP, Mullin JC, Cantilena LR. Terfenadine-ketoconazole interaction. JAMA 1993;269:1513-8.
43. Kilem V, Wanner C, Eisenhauer T, Olbricht CJ, Doll R. O'Grady P, et al. Comparison of pravastatin and lovastatin in renal transplant patients receiving cyclosporine. Transplant Proc 1996;28:3126-8.
44. Pichard L, Fabre I, Fabre G, Domergue J, Aubert BS, Mourad G, et al. Cyclosporin A drug interactions: screening for inducers and inhibitors of cytochrome P-450 (cyclosporin A oxidast) in primary cultures of human hepatocytes and in liver microsomes. Drug Metab Dispos 1990;18:595-605.
45. Bensoussan C, Delaforge M, Mansuy D. Particular ability of cytochromes P4503A to form inhibitory P450-iron-metabolite complexes upon metabolic oxidation of amino drugs. Biochem Pharmacol 1995;49:591-602.
46. Holt V, Kouba M, Dietel M, Vogt G. Stereoisomers of calcium antagonists, which differ markedly in their potencies as calcium blockers, are equally effective in modulating drug transport by P-glycoprotein. Biochem Pharmacol 1992;43:2601-8.
47. Wacher VJ, Wu CY, Benet LZ. Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy. Mol Carcinog 1995; 13:129-34.
48. Yeung PKF, Buckley SJ, Hung OR, Pollak PT, Barclay KD, Feng JDZ, et al. Steady state plasma concentrations of diltiazem and its metabolites in patients and healthy volunteers. Ther Drug Monit 1996;18:40-5.
49. East C, Alivizattos PA, Grundy SM, Jones PH, Farmer JA. Rhabdomyolysis in patients receiving lovastatin after cardiac transplantation. N Engl J Med 1988;318:47-8.